MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'geodon'. Sat, 03 Sep 2011 02:38:02 +0100 http://www.medworm.com/index.php?rid=4622505&cid=t_121649_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FoKxxJSm2UaM%2F Pfizer is holding talks with the US Department of Justice to settle charges the drugmaker committed fraud against government health programs by failing to report discounts and rebates for its Protonix heartburn med, according to a court document. A joint motion filed on March 11 in federal court in Boston asked for extended deadlines related to discovery, among other things, and noted the requests “are necessary to permit the parties to continue to engage in settlement discussions” (read this). The development comes less than a year after 17 states joined a pair of whistleblower lawsuits alleging Wyeth, which is now owned by Pfizer, knowingly failed to report certain discounted prices as required by laws governing the Medicaid program. As a result, Wyeth allegedly avoided payi... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4622505 Tue, 22 Mar 2011 12:28:45 +0100 4622505 http://www.medworm.com/index.php?rid=4507576&cid=t_121649_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2Fhf6Mo6pHvdw%2F The FDA issued a safety alert today about the risks of exposure of nearly two dozen antipsychotics to newborns when the drugs are taken by women during pregnancy. Specifically, the pregnancy section of drug labeling for the entire class was updated to include info about the potential risk for abnormal muscle movements (extrapyramidal signs or EPS) and withdrawal symptoms in newborns. In searching its adverse events database, the agency has, so far, identified 69 cases of neonatal EPS or withdrawal through October 29, 2008, involving all antipsychotics. The symptoms of EPS and withdrawal in newborns may include agitation, abnormally increased or decreased muscle tone, tremor, sleepiness, severe difficulty breathing, and difficulty in feeding. And symptoms varied in severity: in some newborn... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4507576 Tue, 22 Feb 2011 23:28:04 +0100 4507576 http://www.medworm.com/index.php?rid=4179519&cid=t_121649_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FuFNz5Akkn8M%2F Earlier this year, US Senator Chuck Grassley asked all 50 states to provide data on doctors who wrote huge numbers of prescriptions for specific drugs that are paid for by Medicaid programs. The move was prompted by reports indicating certain meds - notably, several widely used antipsychotics, as well as the OxyContin painkiller and Xanax anxiety pill - have been prescribed at particularly high rates. The purpose in launching this inquiry was to determine whether the drugs are overprescribed and, consequently, costing taxpayers unnecessarily. And so Grassley, who is the ranking Republican on the committee and has launched several probes into the pharmaceutical industry, recently followed up with the Department of Health and Human Services in hopes of learning how the agency oversees paymen... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4179519 Thu, 18 Nov 2010 22:19:22 +0100 4179519 http://www.medworm.com/index.php?rid=3556371&cid=t_121649_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2F78zWc96dpoE%2F In blowing the whistle on AstraZeneca for improperly promoting its Seroquel antipsychotic, a $45 million award will be split by James Wetta, a former AZ sales rep, and Stefan Kruszewski, a psychiatrist, for their role in helping the government resolve the charges. In total, the drugmaker is paying $520 million, most of which goes to the federal treasury (background). These two have won such prizes before. Kruszewski earlier sued Pfizer over its marketing of the Geodon antipsychotic and will receive $14.5 million from a $2.3 billion settlement. And Wetta is one of nine whistleblowers who split about $100 million when Lilly paid $1.4 billion to settle charges over illegal marketing of its Zyprexa antipsychotic. In general, whistleblowers were paid $2.39 billion from 1987 to 2009, or 16 perce... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3556371 Wed, 12 May 2010 15:33:48 +0100 3556371 http://www.medworm.com/index.php?rid=3534103&cid=t_121649_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FMdlGW_isPK8%2F The Utah Attorney General filed a lawsuit against Johnson & Johnson and AstraZeneca over allegations they failed to disclose side effects, notably diabetes, caused by their antipsychotics - Risperdal and Seroquel, respectively - and improperly marketed the pills, therefore, causing the state’s Medicaid program to overpay for the medications. However, the lawsuit only says “large sums” were spent without specifying how much the Medicaid program may have overpaid for the drugs. In arguing its case, the state charges the drugs were promoted for unapproved uses, such as treating the elderly for dementia, anxiety, sleep disorders, depression and other behavioral disorders not caused by schizophrenia or bipolar I disorder; treating children and adolescents for general mood... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3534103 Wed, 05 May 2010 11:51:28 +0100 3534103 http://www.medworm.com/index.php?rid=3511776&cid=t_121649_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FiKJQxS2m-mc%2F Earlier this month, the FDA sent Pfizer a warning letter for failing to properly monitor pediatric clinical trials in which at least 13 children with bipolar disorder experienced overdosing that led to restless legs, tremors, involuntary facial movements and a serious skin disorder. This is a big problem for the drugmaker, since Pfizer hopes to receive an extra six months of marketing exclusivity in return for having conducted the pediatric trials. But the dosing scandal could prompt the FDA to request further trials, which would require so much additional time that exclusivity would likely be lost, since the basic Geodon patent expires in 2012. This would also delay pediatric approval, which would expand the possibilities for a drug that generated $1.1 billion in sales last year. But who ... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3511776 Wed, 28 Apr 2010 13:58:00 +0100 3511776 http://www.medworm.com/index.php?rid=3490872&cid=t_121649_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FI2tHrbpETAE%2F The drugmaker was cited for failing to properly monitor pediatric clinical trials in which at least 13 children with bipolar disorder experienced overdosing that led to restless legs, tremors, involuntary facial movements and skin petechiae, which results from bleeding under the skin. The FDA cited Pfizer in an April 9 warning letter that noted the problem was originally found during FDA reviews in 2005. The FDA wrote that “Pfizer failed to properly ensure monitoring of the study referenced above. As a result of inadequate monitoring, widespread overdosing of study subjects at multiple study sites was neither detected nor corrected in a timely manner,” according to the letter. For instance, the FDA cited an internal Pfizer document dated Oct. 3, 2007 and entitled “Safety Info... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3490872 Wed, 21 Apr 2010 11:49:10 +0100 3490872 http://www.medworm.com/index.php?rid=3071466&cid=t_121649_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FLlpwzU6UBgw%2F An FDA official says the agency is considering strengthening the labels to warn about weight gain and diabetes amid concerns the impact could be stronger in children compared to adults, Dow Jones writes. Tom Laughren, who heads the FDA’s division of psychiatric products, says the agency asked drugmakers to provide all their info on metabolic side effects such as increases in blood glucose, which can cause diabetes, and blood cholesterol levels which can lead to cardiovascular problems over time. The labels already mention weight gain and related problems, but Laughren says the FDA is considering putting all the info in the warnings section, which is tantamount to a stronger label. He made his comments yesterday at a pediatric advisory committee meeting held to review the safety of s... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3071466 Wed, 09 Dec 2009 13:43:43 +0100 3071466 http://www.medworm.com/index.php?rid=2939559&cid=t_121649_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FolKsJTYHnyw%2F Nursing homes throughout Illinois are being dosed with powerful psychotropic drugs, leading to tremors, dangerous lethargy and a higher risk of harmful falls or even death, according to an investigation by The Chicago Tribune. Thousands of elderly and disabled people have been affected, many of them drugged without their consent or without a legitimate psychiatric diagnosis that would justify treatment, according to state and federal inspection reports reviewed by the paper. The Trib identified 1,200 violations at Illinois nursing homes involving psychotropic medications since 2001. Those infractions affected 2,900 patients, the paper writes, adding that the actual numbers are likely far higher because regulators inspect some facilities just once every 15 months, and even then they usually... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=2939559 Thu, 29 Oct 2009 12:54:55 +0100 2939559 http://www.medworm.com/index.php?rid=2899194&cid=t_121649_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2F_wiRtPXnyts%2F Tucked into a Pfizer press release this morning about the rosy future that lies ahead - now that Wyeth is securely in its clutches - is this interesting nugget: the big drugmaker has formed an executive compliance committee. Did someone say compliance? This innovative notion comes hard on the news that Pfizer paid a record-setting, ground-breaking, chair-swiveling, eye-rolling, jaw-dropping, $2.3 billion fine for illegally marketing several drugs, including Bextra, Zyvox, Geodon and Lyrica, over several years - even as other corporate integrity agreements were in force. One has to wonder - what took them so long? Maybe it was an ugly round of publicity and lots of cash - that might otherwise be used to retain a few research projects - to prompt ceo Jeff Kindler and his advisors (McKinsey, ... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=2899194 Fri, 16 Oct 2009 12:40:43 +0100 2899194 http://www.medworm.com/index.php?rid=2018097&cid=t_121649_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F475704352%2F The common distinction between first- and second-generation antipsychotics has no scientific basis and should be dropped, according to a paper in The Lancet. A meta-analysis of 150 double-blind studies found little evidence that newer, so-called atypical antipsychotics are more effective than older drugs for symptoms of schizophrenia, MedPage Today writes. The researchers also found that, although newer drugs induced fewer extrapyramidal effects (including tremor, slurred speech, restlessness, movement disorders, among other things) than Haldol, which is also known as haloperidol, this did not occur when compared with low-potency first-generation agents. “Second-generation antipsychotic drugs differ in many properties” - including structure and mode of action as well as clinica... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=2018097 Fri, 05 Dec 2008 13:59:21 +0100 2018097 http://www.medworm.com/index.php?rid=1975632&cid=t_121649_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F460067600%2F – Earlier this week, the FDA advisory committee slammed the rising use of antipsychotics in youngsters, particularly to treat attention deficit disorders. The meds, you see, were approved by the agency for schiozphrenia or bipolar disorder - and only recently for youngsters, in some cases (back story). The trend, however, to prescribe these meds for teenagers and children has actually been widespread, with Medicaid programs in several states reporting rising expenditures for antipsychotics to treat ADD or ADHD. A report issued last year by the University of South Florida found that among children 5 years or younger, 53.8 percent were prescribed antipsychotics for a diagnosis of ADHD. The figure was 48.8 percent for children between 6 and 12 years old (see page 22). The issue is gaini... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1975632 Thu, 20 Nov 2008 22:08:49 +0100 1975632 http://www.medworm.com/index.php?rid=1664631&cid=t_121649_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F349724007%2F The agency did a curious thing this week - a ‘not approvable’ letter was issued to Vanda Pharmaceuticals for a schizophrenia drug. The move stunned investors, who sent the drugmaker’s stock down 73 percent yesterday. But the FDA decision may hold much wider implications for the entire industry - a greater emphasis, perhaps, on comparitive effectiveness. By way of background, Vanda paid Novartis $500,000 for iloperidone, which was intended for psychiatric conditions, in hopes it could be used to treat symptoms of schizophrenia. But while the drug was more effective than a placebo and had similar results as Pfizer’s Geodon, the agency expressed concern about its effectiveness when compared with Johnson & Johnson’s Risperdal and the FDA recommended additiona... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1664631 Tue, 29 Jul 2008 19:20:35 +0100 1664631 http://www.medworm.com/index.php?rid=1522436&cid=t_121649_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F313254592%2F The agency is requiring manufacturers of “conventional” antipsychotic drugs to change the labeling to warn about an increased risk of death associated with the off-label use to treat behavioral problems in older people with dementia. In 2005, the FDA announced similar labeling changes for “atypical” antipsychotic drugs. At that time, Black Box warnings were added, and will now be added to the older “conventional” antipsychotics. The warning for both classes of drugs will say that clinical studies indicate that antipsychotic drugs of both types are associated with an increased risk of death when used in elderly patients treated for dementia-related psychosis, according to an FDA statement. Both classes of drugs are dopamine receptor antagonists work by blocking the action of na... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1522436 Mon, 16 Jun 2008 19:47:12 +0100 1522436 http://www.medworm.com/index.php?rid=1332726&cid=t_121649_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F259581561%2F The so-called atypicals - including Abilify, Risperdal, Zyprexa, Seroquel and Geodon - have been hailed as more effective and easier to tolerate than the older and cheaper kind such as Haldol, which cause tremors and rigid muscles. But the new generation are no better at treating a first episode of schizophrenia, according to a study in The Lancet. Such findings are important because the atypicals are heavily promoted, widely prescribed and expensive. The Dutch researchers studied 498 patients between 18 and 40 years old in Europe and Israel in an open trial lasting 12 months. The patients were randomly assigned to a low-dose version of Haldol, or a higher dose of one of four atypicals. They found that during the subsequent 12-month period, more patients taking Haldol discontinued treatmen... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1332726 Fri, 28 Mar 2008 11:23:29 +0100 1332726 http://www.medworm.com/index.php?rid=1283629&cid=t_121649_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F246941000%2F Antipsychotic Promotional Spending In ‘06 Drug Spending Abilify $329 million Zyprexa $189 million Risperdal $179 million Seroquel $179 million Geodon $119 million Sometimes, money really can’t buy everything. Despite outspending its rivals by huge sums, Bristol-Myers Squibb’s Abilify failed to make much of an impression on a group of psychiatrists and primary care docs surveyed recently. As the first table illustrates, Bristol spent $329 million to promote Abilify in 2006, and this included unspecified costs in reaching docs, samples, DTC ads, detailing, advertising in medical journals, and mailing reprints, according to Sandra Chow, an analyst at Decision Resources, which queried 62 psychiatrists and primary care physicians. This amount was significantly m... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1283629 Thu, 06 Mar 2008 19:54:07 +0100 1283629 http://www.medworm.com/index.php?rid=1036905&cid=t_121649_109_f&fid=34800&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FClinicalPsychologyAndPsychiatryACloserLook%2F%7E3%2F187192410%2Fatypical-antipsychotics-for-elderly.html A recent report in the St. Petersburg Times has indicated that between 20-26% of atypical antipsychotic prescriptions are for elderly people. The drugs are typically given in order to help calm patients. This is interesting because the data supporting their efficacy is very weak (1, 2, 3). While the article in the Times is interesting and discusses the problems with the drugs in terms of side effects, it, along with other media coverage with which I am familiar, is missing a major point: Atypical antipsychotics show minimal effects over the benefit given by a placebo. They are also linked to an increased risk of death. So you are increasing the odds of your patients dying, but you are, according to clinical trial research, providing minimal clinical benefit.Here's a shocking snippet from t... Clinical Psychology and Psychiatry: A Closer Look blogs http://www.medworm.com/rss/comments.php?id=1036905 Mon, 19 Nov 2007 14:32:00 +0100 1036905 http://www.medworm.com/index.php?rid=995008&cid=t_121649_97_f&fid=35050&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmaGazette%2F%7E3%2F177772655%2Fpfizer_incs_geodon_may_control_unresponsive_schizophrenia.html Dr Anthony D. Loebel of Pfizer Inc. ( NYSE:PFE) and colleagues have found that Ziprasidone, sold as Geodon, was well tolerated and showed long term efficiency in patients that suffer from schizophrenia who did not respond to other drug.According to a clinical study published in the Journal of Psychiatry, Loebel and his colleagues studied patients with a diagnosis of treatment-resistant schizophrenia who had been treated for one year with ziprasidone, an atypical antipsychotic. The study involved 62 patients in which 32 received ziprasidone and 30 received clorpromzine. Of the 41 patients who responded to both drugs, 30 were able to maintain this response on ziprasidone."Over 1 year of continuous treatment, ziprasidone was well tolerated, with a relatively low rate of discontinuat... PharmaGazette blogs http://www.medworm.com/rss/comments.php?id=995008 Wed, 31 Oct 2007 17:00:29 +0100 995008 http://www.medworm.com/index.php?rid=882993&cid=t_121649_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F158224083%2F That’s right. The antipsychotic, as you know, can cause weight gain and diabetes. And a survey conducted last month finds that 86 percent of psychiatrists are now writing fewer scrips for Zyprexa. They cited the side effects as the reason, according to Sandra Chow, an analyst at Decision Resources, the market-research firm that queried 151 docs. “Zyprexa, you know, dominated the schizophrenia market just two years ago. In fact, Zyprexa was the number one choice for first-line, second-line and third-line treatment a couple of years ago,” Chow tells Pharmalot. “But the side effects have really changed the perception.” The fall from grace follows a year in which litigation documents were leaked indicating Lilly allegedly hid side-effect data from docs, and sever... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=882993 Tue, 18 Sep 2007 19:57:51 +0100 882993 http://www.medworm.com/index.php?rid=841907&cid=t_121649_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F152451613%2F That’s what the rate of scrips for antipsychotics written for kids is being called in the wake of a study this week in the Archives of General Psychiatry. The research showed that there’s been a 40-fold increase over nine years in the number of kids diagnosed with bipolar disorder, fueling an explosion in sales of antipsychotic meds made by Johnson & Johnson, AstraZeneca and Pfizer. The number of scrips written for kids doubled to 4.4 million between 2003 and 2006, according to data provided to Bloomberg New by Wolters Kluwer, a research firm. The expanded use of bipolar disorder as a pediatric diagnosis has made children the fastest-growing part of the $11.5 billion US market for antipsychotic drugs. Some experts say the treatments are bringing needed help to troubled kid... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=841907 Wed, 05 Sep 2007 10:57:53 +0100 841907 http://www.medworm.com/index.php?rid=800177&cid=t_121649_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F144373788%2F The drugmaker received a warning letter that a professional file card, which is basically promotional material, overestimated the effectiveness of its Alzheimer’s med, contained misleading info concerning risks and unsubstantiated superiority claims, and recommended an unapproved combo with another drug. You can look at the file card here. “These violations are concerning from a public health perspective because they suggest that Exelon is safer or more effective than has been demonstrated, and they encourage the use of Exelon in circumstances other than those for which the drug has been shown to be safe and effective,” wrote Tom Abrams, who heads the FDA’s Division of Drug Marketing, Advertising and Communications, in the letter to Alex Gorsky, who heads Novartis p... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=800177 Wed, 15 Aug 2007 12:06:26 +0100 800177 http://www.medworm.com/index.php?rid=797221&cid=t_121649_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F143781157%2F The drugmaker omitted important risk info and made unsubstantiated claims that Geodon is better than another drug, according to a July 16 warning letter posted on the FDA web site. And the agency asked Pfizer to stop running the ad, which appeared in an unnamed medical journal. The FDA wrote that the ad, which you can see by clicking on this link, included some info about potential side effects from the injectable version of Geodon, but didn’t mention “other serious warnings and precautions,” such as the possibility of neuroleptic malignant syndrome, tardive dyskinesia, hyperglycemia and diabetes. The ad also suggested Geodon was more effective than a generic drug, haloperidol, “when this has not been demonstrated by substantial evidence or substantial clinical expe... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=797221 Mon, 13 Aug 2007 20:45:05 +0100 797221 http://www.medworm.com/index.php?rid=676728&cid=t_121649_140_f&fid=35439&url=http%3A%2F%2Fbipolarsoupkitchen-stephany.blogspot.com%2F2007%2F06%2Fgeodon-pfizer-another-failed-trial.html The common practice among psychiatrists is to medicate bipolar with a mood stabilizer and an antipsychotic thrown in for prevention or good measure, maybe just because they don't know any better.I discussed in length the failure of Seroquel with 3 members of my family. All 3 had different symptoms, and all 3 had different reactions which were negative in outcome using Seroquel, causing patient to stop using the drug.When one family member could not tolerate the Seroquel, though on Lamictal at the time, the psychiatrist replaced Seroquel with Geodon.Bipolar Mania Medication-GeodonFrom Pfizer's site:"Bipolar disorder is an illness of severe mood swings. It is also called manic depression. If you have the illness, you may go back and forth from high moods (mania) to low moods (depression). Ov... soulful sepulcher blogs http://www.medworm.com/rss/comments.php?id=676728 Tue, 12 Jun 2007 17:02:00 +0100 676728 http://www.medworm.com/index.php?rid=644902&cid=t_121649_109_f&fid=34800&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FClinicalPsychologyAndPsychiatryACloserLook%2F%7E3%2F120786789%2Fadvertising-as-education-cme-part-deux.html This article is derived from the planning teleconference “Evaluating the Evidence: Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and Beyond,” which was held on May 10, 2006, and was independently developed by the CME Institute of Physicians Postgraduate Press, Inc., and Health and Wellness Education Partners (HWeP) pursuant to an educational grant from Pfizer and addition support from HWP Publishing Dr. Nasrallah is a consultant for, has received honoraria from, and been on the speakers/advisory boards for Abbott, AstraZeneca, Janssen, Pfizer, and Shire and has received grant/research support from AstraZeneca, Janssen, and Pfizer. Content development and writing support for this article was provided in part by an independent writer contracted by HWeP: Martin Kor... Clinical Psychology and Psychiatry: A Closer Look blogs http://www.medworm.com/rss/comments.php?id=644902 Wed, 30 May 2007 12:21:00 +0100 644902